[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587959":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":19,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":19,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":19,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Teclistamab","EXPERIMENTAL","Teclistamab will be administered via a subcutaneous injection",[13],"Drug: Teclistamab (Tec)",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Teclistamab (Tec)",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Kaini Shen","CONTACT","86-13693339884","shenkaini3@sina.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":42,"phoneExt":19,"email":25},"86+13693339884",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Jian Li","Professor","100587959","phase-2-teclistamab-in-previously-treated-al-amyloidosis-100587959",false,"NCT06935162","Teclistamab in Previously Treated AL Amyloidosis","Teclistamab for Previously Treated Light-chain Amyloidosis Patients, a Phase II Study","Inclusion Criteria:\n\n* Biopsy confirmed AL amyloidosis\n* Patients must have received at least one line of treatment, including daratumumab and bortezomib\n* Relapse from previous treatment, or less than partial response after two cycles of treatment\u002Fless than very good partial response after three cycles of treatment\n* dFLC \\> 50mg\u002FL\n\nExclusion Criteria:\n\n* Previous anti-BCMA targeted therapy\n* Co-morbidity of uncontrolled infection\n* Co-morbidity of other active malignancy\n* Co-diagnosis of multiple myeloma or waldenstrom macroglobulinemia\n* Co-morbidity of grade 2 Mobitz II or grade 3 atrioventricular block (expect for those with implanted pacemaker)\n* Co-morbidity of sustained or recurrent nonsustained ventricular tachycardia\n* Seropositive for human immunodeficiency virus\n* Hepatitis B virus (HBV)-DNA \\> 1000 copies\u002FmL\n* Seropositive for hepatitis C (except in the setting of a sustained virologic response)\n* Neutrophil \\\u003C1×10E9\u002FL, hemoglobin \\\u003C 8g\u002FdL, or platelet \\\u003C 75×10E9\u002FL.\n* Severely compromised hepatic or renal function: alanine transaminase (ALT) or aspertate aminotransferase (AST) \\> 5 × upper limit of normal (ULN), total bilirubin \\> 2 × ULN, eGFR \\\u003C 20 mL\u002Fmin, or receiving renal replacement therapy","ALL","18 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab",[64],"AL Amyloidosis","2025-05-21",{"date":67,"type":68},"2025-05-25","ACTUAL",{"date":65,"type":68},{"date":71,"type":58},"2028-12-31",{"name":5,"class":6},1]